Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Overview

The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial is a multicenter, randomized, controlled clinical trial of 1400 patients that will include approximately 60 enrolling sites. The study hypotheses are that treatment of hyperglycemic acute ischemic stroke patients with targeted glucose concentration (80mg/dL – 130 mg/dL) will be safe and result in improved 3 month outcome after stroke.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: November 19, 2018

Detailed Description

Eligible subjects must be randomized within 12 hours of stroke symptom onset and either have type 2 diabetes and glucose concentrations of over 110 mg/dL or no history of diabetes and glucose concentrations of 150 mg/dL or higher on initial evaluation. The enrolling sites include the Neurological Emergencies Treatment Trials (NETT) sites as well as non NETT sites from all over the United States. The study evaluates the safety and efficacy of targeted glucose control (treatment group – IV insulin with target 80-130 mg/dl) verses control therapy of sub q insulin plus basal insulin with target glucose less than 180 mg/ dL.

Interventions

  • Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL
    • Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
  • Drug: Standard Care control – sliding scale insulin to keep glucose less than 180 mg/dL
    • Sliding scale sub q insulin given will be given up to 4 times per day based on glucose concentration. It will be given only if glucose concentration greater than or equal to 180 mg/dL.

Arms, Groups and Cohorts

  • Experimental: IV insulin drip with target glucose 80 mg/dL – 130 mg/dL
    • The intervention arm will have a targeted glucose concentration of 80-130 mg/dL. IV insulin drip will be titrated to keep glucose concentration in this range.
  • Active Comparator: Sub Q insulin to keep glucose less than 180 mg/dL
    • This standard care arm will get sub q insulin sliding scale to keep glucose concentration less than 180 mg/dL

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants With a Favorable Modified Rankin Scale (Yes/No)
    • Time Frame: 90 days (-14/+30 days)
    • Favorable for the primary efficacy outcome is defined as modified Rankin Scale (mRS) score of 0 in patients with mild stroke (baseline NIHSS 3-7), mRS 0 or 1 in patients with moderate stroke (baseline NIHSS 8-14), and mRS 0, 1 or 2 in patients with severe stroke (baseline NIHSS 15-22) at 90 days with a pre-specified range of acceptable days of 76 -120 days. The mRS is a stroke outcome scale used to assess functional status after stroke. It consists of seven levels (0-6) where 0 indicates no residual symptoms at all, 5 indicates severe disability and 6 indicates death. The person collecting the mRS score was to be blinded to the participant’s treatment group assignment.
  • Number of Participants With Severe Hypoglycemia (Blood Glucose < 40mg/dL)
    • Time Frame: 72 hours
    • Severe hypoglycemia (blood glucose < 40mg/dL) is the primary safety outcome and will be measured during the 72 hour treatment period.

Secondary Measures

  • Number of Participants With a Favorable NIHSS
    • Time Frame: Follow up (Max 164 days)
    • The NIHSS (National Institutes of Health Stroke Scale) score ranges from 0 to 42, with higher scores indicating greater neurological deficits. A favorable NIHSS was defined as a score of 0 or 1 on the NIHSS at 90 days post randomization.
  • Number of Participants With a Favorable Barthel Index
    • Time Frame: Follow up (Max 164 days)
    • Favorable outcomes for the Barthel Index was defined as a score of 95-100 on the BI at 90 days post randomization. Barthel – Barthel Index for Activities of Daily Living (ADL) assesses functional independence, generally in stroke patients. Scores range from 0-100 with higher scores indicating greater ability to perform activities of daily living.
  • Stroke Specific Quality of Life (SSQOL)
    • Time Frame: Follow up (Max 164 days)
    • Stroke Specific Quality of Life. Scores range from 1-5 with higher scores indicating better quality of life

Participating in This Clinical Trial

Inclusion Criteria

1. Age 18 years or older 2. Clinical diagnosis of ischemic stroke defined as acute neurological deficit occurring in one or more cerebral vascular territories. Neuroimaging must be done to exclude intracranial hemorrhage (ICH). 3. Randomization must be within 12 hours after stroke symptom onset and treatment is recommended, but not required, to begin within 3 hours after hospital arrival. If time of symptom onset is unclear or patient is awakening with stroke symptoms, the time of onset will be the time the patient was last known to be normal. 4. Known history of type 2 diabetes mellitus and glucose >110 mg/dL OR admission blood glucose ≥150 mg/dL in those w/o known diabetes mellitus 5. Baseline NIHSS score of 3-22 6. Pre-stroke modified Rankin Scale score = 0 for patients with an NIHSS score of 3-7. Pre-stroke modified Rankin Scale score = 0 or 1 for patients with an NIHSS score of 8-22. 7. Able to provide a valid informed consent to be in the study (self or their authorized legally accepted representative). The approved consent form must be signed and dated in accordance with federal and institutional guidelines. Exclusion Criteria:

1. Known history of type 1 diabetes mellitus 2. Substantial pre-existing neurological or psychiatric illness that would confound the neurological assessment or other outcome assessment 3. Having received experimental therapy for the enrollment stroke. IV tPA (up to 4.5 hrs) or IA tPA are allowed as are IA therapies including use of FDA cleared devices. Non FDA cleared devices are considered experimental and are excluded. 4. Pregnant or breast-feeding at the time of study entry 5. Other serious conditions that make the patient unlikely to survive 90 days 6. Inability to follow the protocol or return for the 90 day follow up 7. Renal dialysis (including hemo or peritoneal dialysis)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Virginia
  • Collaborator
    • Neurological Emergencies Treatment Trials Network (NETT)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Karen C. Johnston, Principal Investigator – University of Virginia
  • Overall Official(s)
    • Karen C Johnston, MD, MSc, Study Chair, University of Virginia
    • Christiana Hall, MD, MS, Principal Investigator, UT Southwestern
    • Askiel Bruno, MD, MS, Principal Investigator, Augusta University
    • Valerie Durkalski, PhD, Principal Investigator, Medical University of South Carolina
    • William Barsan, MD, Principal Investigator, University of Michigan
    • Kevin Barrett, MD, Principal Investigator, Mayo Clinic

Citations Reporting on Results

Johnston KC, Bruno A, Pauls Q, Hall CE, Barrett KM, Barsan W, Fansler A, Van de Bruinhorst K, Janis S, Durkalski-Mauldin VL; Neurological Emergencies Treatment Trials Network and the SHINE Trial Investigators. Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. JAMA. 2019 Jul 23;322(4):326-335. doi: 10.1001/jama.2019.9346. Erratum In: JAMA. 2019 Nov 5;322(17):1718.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.